Overview
ARA-290, also known by its clinical research name Cibinetide (CAS number 1208243-50-8), is a synthetic peptide derived from a specific region of the erythropoietin (EPO) protein — a naturally occurring hormone involved in red blood cell production. Rather than mimicking EPO's blood-forming activity, ARA-290 is specifically designed to interact with what is known as the innate repair receptor, placing it in the broader category of tissue-protective and immunomodulatory peptides. Researchers have been studying this peptide in the context of inflammation, metabolic dysfunction, and neural responses, with published studies exploring its potential relevance to conditions involving cognitive function and traumatic brain injury models. ARA-290 is intended strictly for laboratory and preclinical research use only and is not approved for human consumption or therapeutic application.
Research & Bioactivity
ARA-290 is a cyclic helix B surface peptide derived from erythropoietin (EPO) that has been investigated in research contexts for its potential tissue-protective and anti-inflammatory properties, distinct from EPO's traditional erythropoietic functions. Studies have examined its activity in relation to neuroprotection, with research conducted in mouse models of cerebral ischemic stroke — specifically middle cerebral artery occlusion — exploring its interactions with the beta-common receptor (βCR) and effects on neurological outcomes. Researchers have also investigated EPO-derived peptides, including ARA-290, in the context of peripheral nerve injury, where animal and preclinical studies have explored mechanisms related to nerve repair and tissue protection. Additional research has looked at the broader landscape of erythropoietin derivatives in traumatic brain injury models, examining how such peptides may interact with inflammatory and neuroprotective pathways across distinct phases of injury. Studies have further examined related cyclic peptides in autoimmune and inflammatory conditions, such as experimental autoimmune uveitis in mice, contributing to the understanding of how this class of compounds may modulate immune signaling. Research into ARA-290 remains an active area of preclinical investigation, with studies continuing to probe its mechanisms of action across inflammatory, metabolic, and neurological research models.
Published Research
Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.
Alasousi D, Braysh K, D'Souza L, Islam S, Alhawaj F, et al. — 2026
Type 2 diabetes (T2D) is associated with cognitive impairment, with executive functions such as cognitive flexibility being particularly vulnerable. Growing evidence suggests that chronic inflammatory and metabolic stress contributes to diabetes -related brain dysfunction, yet behavioral assessment in animal models is often confounded by anxiety, altered motivation, and reduced response vigor. In this study, we used a translational touchscreen-based operant platform to distinguish associative learning from executive cognitive flexibility in db/db mice, a well-established genetic model of T2D, and to evaluate the effects of the non-erythropoietic erythropoietin derived peptide ARA 290. Male db/db mice and age matched db/m heterozygote lean controls were tested using pairwise visual discrimination to assess associative learning and reversal learning to probe cognitive flexibility. Metabolic function was evaluated using glucose and insulin tolerance tests, while immune and metabolic effects of ARA 290 were evaluated by flow cytometry and RNA-seq. Db/db mice displayed delayed task engagement and longer response latencies during pretraining and acquisition, yet maintained intact associative learning accuracy. In contrast, they exhibited pronounced impairments in cognitive flexibility during reversal learning, characterized by increased perseveration and reduced adaptation to changed reward contingencies. Treatment with ARA 290 improved insulin sensitivity and altered circulating monocyte proportions but did not rescue deficits in executive cognitive flexibility. RNA-seq of the hippocampus revealed enrichment of immune pathways consistent with chronic low-grade inflammation, providing molecular context for the observed behavioral phenotype. Together, these findings demonstrate that T2D selectively impairs executive cognitive flexibility while sparing basic associative learning, and that improvement in peripheral metabolic function and altered monocyte proportions are insufficient to restore executive cognition. This work highlights the value of touchscreen-based paradigms for resolving distinct cognitive domains in metabolic disease and highlights the need to target brain specific immunometabolic mechanisms to address diabetes-associated cognitive dysfunction.
Phase-targeted erythropoietin derivatives for traumatic brain injury: bridging mechanisms to precision therapy.
Sun Y, Song B, Zhang Y, Zhang Y, Zhou L — 2025
Traumatic brain injury (TBI) unfolds through a well-defined chronology-hyperacute excitotoxic and inflammasome bursts, acute apoptotic and blood-brain-barrier failure, and subacute neurovascular remodeling-that no single-pathway drug can adequately cover. Recombinant erythropoietin (EPO) limits secondary damage in animals, yet its erythropoietic drive and thrombotic liability have stalled clinical adoption. This review integrates structural biology, pharmacology and translational data on four engineered EPO derivatives-carbamylated EPO, asialo-EPO, darbepoetin alfa and the helix-B surface peptide (HBSP/cibinetide)-that decouple cytoprotection from red-cell stimulation. We first outline how specific modifications (carbamylation, desialylation, hyper-glycosylation or helix truncation) bias EPOR signaling toward PI3K-AKT and away from JAK2-STAT5. We then match each derivative to its optimal injury window. Meta-analyses of randomized trials suggest a possible trend toward lower short-term mortality without a consistent functional benefit or thrombotic signal. By integrating molecular mechanisms, experimental findings, and early clinical observations, this review outlines hypotheses and future trial frameworks for phase-targeted, erythropoietin-based neuroprotection. Further controlled studies are required to establish safety, efficacy, and optimal therapeutic timing before translation to routine clinical use.
Anti-Inflammatory Effects of Clarstatin, a Shared-Epitope-Antagonistic Cyclic Peptide, on Experimental Autoimmune Uveitis in Mice.
Merzbach S, Schumacher-Klinger A, Klazas M, Hoffman A, Lazarovici P, et al. — 2025
PURPOSE: Polymorphism and mutations of human leukocyte antigens (HLAs) and calreticulin are risk factors for uveitis. Here, we sought to determine the therapeutic effects of Clarstatin, a cyclic peptide antagonist of the HLA shared-epitope-calreticulin interaction, in experimental autoimmune uveitis (EAU) models. METHODS: Mice were injected with Clarstatin intraperitoneally and its effect was compared to that of corticosteroid. EAU was evaluated clinically and histologically. Ocular infiltration of CD45+ hematopoietic cells and splenocyte CD4+ expression were determined using immunofluorescence and flow cytometry (fluorescence-activated cell sorting [FACS]). ELISA was used to measure the ocular level of the proinflammatory cytokines. RESULTS: Clarstatin significantly ameliorated the severity of EAU in the C57BL/6J mild and the B10.RIII severe mice models. There was a significant dose and time-dependent decrease, in the range of 30% to 80%, in the clinical score (P < 0.05), histological score (P < 0.05), and number of retinal and spleen CD45+ cells (P < 0.05 and P < 0.001, respectively), a comparable effect to corticosteroid. Clarstatin reduced the intraocular levels of interleukin 6 (IL-6; P < 0.05) and monocyte chemoattractant protein-1 (MCP-1; P < 0.01) by 41% and 59%, respectively. CONCLUSIONS: Systemic delivery of Clarstatin significantly improved mild and severe EAU. Its potential anti-inflammatory therapeutic effects represent a novel mode of treatment in ocular inflammation. It may also be a relevant treatment modality in systemic autoimmune conditions in which calreticulin plays a role in their pathogenesis.
The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury.
Liu G, Liang J, Li W, Jiang S, Song M, et al. — 2024
Peripheral nerve injury seriously endangers human life and health, but there is no clinical drug for the treatment of peripheral nerve injury, so it is imperative to develop drugs to promote the repair of peripheral nerve injury. Erythropoietin (EPO) not only has the traditional role of promoting erythropoiesis, but also has a tissue-protective effect. Over the past few decades, researchers have confirmed that EPO has neuroprotective effects. However, side effects caused by long-term use of EPO limited its clinical application. Therefore, EPO derivatives with low side effects have been explored. Among them, ARA290 has shown significant protective effects on the nervous system, but the biggest disadvantage of ARA290, its short half-life, limits its application. To address the short half-life issue, the researchers modified ARA290 with thioether cyclization to generate a thioether cyclized helical B peptide (CHBP). ARA290 and CHBP have promising applications as peptide drugs. The neuroprotective effects they exhibit have attracted continuous exploration of their mechanisms of action. This article will review the research on the role of EPO, ARA290 and CHBP in the nervous system around this developmental process, and provide a certain reference for the subsequent research.
Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke.
Wang RL, Yang ZH, Huang YY, Hu Y, Wang YL, et al. — 2024
AIM: To explore the neuroprotective effects of ARA290 and the role of β-common receptor (βCR) in a mouse model of middle cerebral artery occlusion (MCAO). METHODS: This study included male C57BL/6J mice that underwent MCAO and reperfusion. The neuroprotective effect of ARA290 on MCAO-induced brain injury was investigated using neurological function tests (Longa and modified neurological severity score). Cerebral infarction was examined by 2, 3, 5-triphenyl tetrazolium chloride staining, neuronal apoptosis was assessed by immunofluorescence staining, blood parameters were measured using a flow cytometry-based automated hematology analyzer, liquid chromatography with tandem mass spectrometry was used to identify the serum metabolomics signature, inflammatory cytokines and liver index were detected by commercially available kits, and the protein levels of the erythropoietin (EPO) receptor and βCR were measured by western blot. RESULTS: ARA290 exerted a qualitatively similar neuroprotective effect after MCAO as EPO. ARA290 significantly reduced neuronal apoptosis and the level of inflammatory cytokines in the brain tissue. However, ARA290's neuroprotective effect was significantly suppressed following the injection of siRNA against βCR. CONCLUSION: ARA290 provided a neuroprotective effect via βCR in cerebral ischemic mice without causing erythropoiesis. This study provides novel insights into the role of ARA290 in ischemic stroke intervention.